<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="2223">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on December 16, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05132218</url>
  </required_header>
  <id_info>
    <org_study_id>BD-EN-IV002</org_study_id>
    <nct_id>NCT05132218</nct_id>
  </id_info>
  <brief_title>Ensatinib in alK-positive Patients Undergoing Initial Treatment for Advanced Non-small Cell Lung Cancer</brief_title>
  <acronym>EFLRWR</acronym>
  <official_title>Prospective Exploratory Real World Study of Ensatinib in alK-positive Patients Undergoing Initial Treatment for Advanced Non-small Cell Lung Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Beijing Cancer Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Betta Pharmaceuticals Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Beijing Cancer Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The experimental design is exploratory, single-arm, multi-center, real-world research.&#xD;
&#xD;
      Ensatinib 225mg qd A prospective and exploratory real-world study of Ensatinib for&#xD;
      ALK-positive advanced non-small cell lung cancer patients Test purposes Exploring the real&#xD;
      world, Ensatinib is effective for the newly treated ALK+ advanced NSCLC&#xD;
&#xD;
        1. Efficacy and safety;&#xD;
&#xD;
        2. The relationship between molecular mechanism and curative effect;&#xD;
&#xD;
        3. Ensatinib resistance mechanism;&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Enrolled patients:&#xD;
&#xD;
        1. stage IIIB or stage IV NSCLC&#xD;
&#xD;
        2. Each center confirmed ALK+ by tissue samples (Abbott FISH, VENTANA ALK D5F3, NGS method&#xD;
           confirmation);&#xD;
&#xD;
        3. Without any ALK-TKI treatment; Study endpoint&#xD;
&#xD;
      Primary endpoint:&#xD;
&#xD;
      According to the RECIST1.1 standard, the progression-free survival (PFS) assessed by the&#xD;
      investigator;&#xD;
&#xD;
      Secondary endpoint:&#xD;
&#xD;
      According to the RECIST1.1 standard, the objective response rate (ORR) evaluated by the&#xD;
      investigator; the time to treatment failure (TTF); according to the RECIST1.1 standard, the&#xD;
      ORR and PFS of patients with different ALK fusion subtypes evaluated by the investigator;&#xD;
      total Lifetime (OS); safety;&#xD;
&#xD;
      Exploratory endpoint:&#xD;
&#xD;
      The correlation between the biomarkers in blood or/and tissue samples and the efficacy of&#xD;
      Ensatinib; the resistance mechanism of Ensatinib;&#xD;
&#xD;
      The sample size is determined:&#xD;
&#xD;
      The plan is to analyze 60-80 patients with EML4-ALK fusion v1 and v3 subtypes. Based on the&#xD;
      proportion of patients with both subtypes in ALK-positive patients, the proportion is about&#xD;
      40%. Based on the 20% dropout rate, the plan is to include ALK without distinction. 180&#xD;
      patients with fusion subtype; statistical methods:&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 19, 2021</start_date>
  <completion_date type="Anticipated">October 30, 2024</completion_date>
  <primary_completion_date type="Anticipated">October 30, 2022</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>progression-free survival</measure>
    <time_frame>2021.09.27-2024.12.30</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>overall survival</measure>
    <time_frame>2021.09.27-2024.12.30</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time-to-TreatmentFailure</measure>
    <time_frame>2021.09.27-2024.12.30</time_frame>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">180</enrollment>
  <condition>ALK Positive</condition>
  <condition>NSCLC Stage IIIB</condition>
  <condition>NSCLC Stage IV</condition>
  <arm_group>
    <arm_group_label>Ensatinib for treated patients with ALK-positive advanced non-small cell lung cancer</arm_group_label>
    <description>Ensatinib 225mg QD Until the disease progresses or intolerance</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ensatinib</intervention_name>
    <description>Prospective, exploratory, single-arm, multi-center, real-world research</description>
    <arm_group_label>Ensatinib for treated patients with ALK-positive advanced non-small cell lung cancer</arm_group_label>
    <other_name>BD-EN-IV002</other_name>
  </intervention>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      1. The patient's tumor tissue sample before taking Ensatinib&#xD;
&#xD;
        2. The patient's baseline blood sample within the first week before taking Ensantinib&#xD;
&#xD;
        3. Blood samples of patients 4-6 weeks after taking Ensatinib&#xD;
&#xD;
        4. Blood samples within 4 weeks after the patient's disease progression&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Single arm real world study of non-small cell lung cancer; stage IIIB or stage IV ALK&#xD;
        positive NSCLC；&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. stage IIIB or stage IV NSCLC by histology or cytology;&#xD;
&#xD;
          2. All centers confirmed ALK positive by tissue samples (Abbott FISH, VENTANA ALK D5F3,&#xD;
             NGS method confirmation);&#xD;
&#xD;
          3. Without any ALK-TKI treatment;&#xD;
&#xD;
          4. Voluntarily and capable of following the trial and follow-up procedures;&#xD;
&#xD;
          5. Able to understand the nature of the trial, and be able to complete the signing of a&#xD;
             written informed consent form.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  1. Pereceived any ALK-TKI treatment ; 2. Received any chemotherapy within 4 weeks, or&#xD;
             underwent major surgery or radiotherapy within the last 14 days; 3. The investigator&#xD;
             believes that the patient is not suitable for Ensatinib treatment.&#xD;
&#xD;
        Had a stem cell or organ transplant. 4. Having serious cardiovascular disease, including&#xD;
        but not limited to: 5.Sino - QTcF interval ≥450 ms or other significant ECG abnormalities.&#xD;
        According to the study, researchers either ruled that hypertension was poorly controlled&#xD;
        (systolic blood pressure &gt;160 mmHg or diastolic blood pressure &gt;100mmHg).&#xD;
&#xD;
        6. Dysphagia, active gastrointestinal disease, or other disease that significantly affects&#xD;
        drug absorption, distribution, metabolism, and excretion.&#xD;
&#xD;
        7. Previous history of interstitial lung disease, drug-induced interstitial lung disease,&#xD;
        radioactive pneumonia requiring steroid treatment, or any indication of clinically active&#xD;
        interstitial lung disease.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Jun Zhao, PhD</last_name>
    <phone>13521469335</phone>
    <email>ohjerry@163.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Xue Yang Yang</last_name>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Beijing Cancer Hospital</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100176</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jie Li, PhD</last_name>
      <phone>010-88196391</phone>
      <email>xiaotong10241@sina.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>October 26, 2021</study_first_submitted>
  <study_first_submitted_qc>November 16, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">November 24, 2021</study_first_posted>
  <last_update_submitted>November 16, 2021</last_update_submitted>
  <last_update_submitted_qc>November 16, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 24, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Beijing Cancer Hospital</investigator_affiliation>
    <investigator_full_name>Jun Zhao</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

